Gold prices steady with focus on Ukraine-Russia, Jackson Hole
VANCOUVER - AbCellera Biologics Inc. (NASDAQ:ABCL), currently trading near $4.24 and showing strong momentum with a 33% gain over the past six months, has initiated dosing in a Phase 1 clinical trial of ABCL635, a potential treatment for moderate-to-severe vasomotor symptoms associated with menopause, the company announced Thursday alongside its second quarter financial results.
The randomized, placebo-controlled, double-blind study is evaluating safety, pharmacokinetics, pharmacodynamics, and the frequency and severity of hot flashes with subcutaneous doses of ABCL635 in healthy men and postmenopausal women. Initial safety and efficacy data are expected by mid-2026.
The company also reported that a Phase 1 trial of ABCL575 for moderate-to-severe atopic dermatitis has begun, and that ABCL688, targeting autoimmunity, has advanced to IND-enabling studies.
AbCellera posted a net loss of $34.7 million, or $0.12 per share, for the second quarter, compared to a $36.9 million loss, or $0.13 per share, in the same period last year. Revenue increased to $17.1 million from $7.3 million in Q2 2024. According to InvestingPro data, analysts anticipate continued sales pressure, with two analysts recently revising earnings estimates downward for the upcoming period.
Research and development expenses were $39.2 million, down from $40.9 million a year earlier, reflecting the company’s increased focus on internal pipeline development.
The company reported $580 million in cash, cash equivalents, and marketable securities, plus approximately $173 million in available non-dilutive government funding, bringing total available liquidity to approximately $753 million. This strong cash position, reflected in InvestingPro’s Financial Health Score of "FAIR," is supported by a healthy current ratio of 10.15, indicating robust short-term financial stability.
AbCellera has reached a cumulative total of 102 partner-initiated program starts with downstreams, up 10% from 93 in June 2024, and has advanced 18 molecules to the clinic, a 29% increase from 14 a year ago.
The information in this article is based on a press release statement from AbCellera. For comprehensive analysis and additional insights, including 12 key ProTips and detailed financial metrics, explore AbCellera’s full Pro Research Report, available exclusively on InvestingPro.
In other recent news, AbCellera Biologics has received authorization from Health Canada to initiate a Phase 1 clinical trial for its investigational antibody medicine, ABCL575, aimed at treating moderate-to-severe atopic dermatitis. This trial is expected to begin in the third quarter of 2025, focusing on the safety and pharmacokinetics of the drug. Additionally, AbCellera is set to start another Phase 1 trial for ABCL635, targeting vasomotor symptoms in postmenopausal women, following Health Canada’s approval. Truist Securities has adjusted its price target for AbCellera shares to $10.00 while maintaining a Buy rating, citing optimism about the ABCL635 program due to the significant unmet need and market potential. Leerink Partners has also assumed coverage on AbCellera with an Outperform rating, highlighting the company’s strategic shift towards developing its own therapeutic candidates. At its recent Annual Meeting of Shareholders, AbCellera announced the election of two Class II directors, Carl L. G. Hansen and Michael Hayden, for a three-year term. These developments mark significant steps in AbCellera’s journey to becoming a clinical-stage biotech company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.